---
title: "Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284443031.md"
description: "Mechelen, Belgium - April 28, 2026 - Galapagos NV disclosed that during the Annual and Extraordinary Shareholders’ Meetings on April 28, 2026, all resolutions put forth were successfully passed. Galapagos NV, listed on Euronext and NASDAQ under the ticker symbol GLPG, confirmed the approval of all proposed resolutions during the meetings."
datetime: "2026-04-28T20:03:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284443031.md)
  - [en](https://longbridge.com/en/news/284443031.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284443031.md)
generator: "portal-rs"
---

# Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026

Mechelen, Belgium - April 28, 2026 - Galapagos NV disclosed that during the Annual and Extraordinary Shareholders’ Meetings on April 28, 2026, all resolutions put forth were successfully passed. Galapagos NV, listed on Euronext and NASDAQ under the ticker symbol GLPG, confirmed the approval of all proposed resolutions during the meetings.

### Related Stocks

- [GLPG.US](https://longbridge.com/en/quote/GLPG.US.md)

## Related News & Research

- [Galapagos (0JXZ) Gets a Sell from Barclays](https://longbridge.com/en/news/295495555.md)
- [Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul](https://longbridge.com/en/news/284587561.md)
- [Short Interest in Galapagos NV (NASDAQ:GLPG) Expands By 20.4%](https://longbridge.com/en/news/283206270.md)
- [Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout](https://longbridge.com/en/news/280351103.md)
- [Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition](https://longbridge.com/en/news/280356780.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**